Announcements Trials
Browse Landscape

Phase

Phase 2 5

Status

Active not recruiting 5Unknown 3Completed 3Withdrawn 1Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 5

Conditions

Multiple Myeloma 57Recurrence 7Neoplasms, Plasma Cell 5Neoplasms 4Smoldering Multiple Myeloma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Paraproteinemias 1Immunoglobulin Light-chain Amyloidosis 1Glioblastoma 1Disease 1Chromosome 17 deletion 1

Interventions

Dexamethasone 13Lenalidomide 11daratumumab 5carfilzomib 5Bortezomib 5Calcium Dobesilate 4Whole-Body Irradiation 3Tacrolimus 3Mycophenolic Acid 3Melphalan 3Cyclophosphamide 3ixazomib 2isatuximab 2fludarabine phosphate 2fludarabine 2belantamab mafodotin 2Etoposide 2venetoclax 1thymoglobulin 1selinexor 1pomalidomide 1poly ICLC 1citarinostat 1Transplantation 1Thalidomide 1Sirolimus 1Rituximab 1Positron Emission Tomography Computed Tomography 1Pharmaceutical Preparations 1Peripheral Blood Stem Cell Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Active not recruiting × Neoplasms, Plasma Cell × daratumumab × Clear all
NCT03500445 2026-04-13

Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma

University of Chicago

Phase 2 Active not recruiting
75 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04151667 2026-03-11

Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
33 enrolled 11 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04052880 2025-07-20

Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM

Icahn School of Medicine at Mount Sinai

Phase 2 Active not recruiting
17 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04782687 2025-01-16

Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

US Oncology Research

Phase 2 Active not recruiting
73 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Neoplasms, Plasma Cell

NCT03289299 2023-12-12

ASCENT

International Myeloma Foundation

Phase 2 Active not recruiting
87 enrolled
Plasma cell

Smoldering Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡